

# Meeting Notice and Agenda

Cannabis Advisory Committee – Medical-Use Subcommittee  
Wednesday, July 10, 2024 – 9:00 am.

Pursuant to Government Code section 11123, this meeting will be held by teleconference.

## Notice to the Public

The Cannabis Advisory Committee’s (CAC) Medicinal Use Subcommittee will hold a meeting on July 10<sup>th</sup>, 2024, at 9:00 a.m. CAC subcommittee meetings are live-streamed and open to the public. No registration is required.

To view or participate in the meeting, please join by computer or phone at the meeting time:

- To join by computer (WebEx Event):
  - Webinar #: 2664 863 1224
  - Password: MJbG9YU3jj3 (65249983 when dialing from a phone or video system)
- To join by phone, call: +1-650-479-3208, Access code: 266 486 31224
- View [instructions](#) for connecting to the meeting.

Meeting materials will be available on the [CAC page](#) of the Department of Cannabis Control (DCC) website. Meeting materials will be published as they become available.

## Public Participation in the Meeting

The public can play an active role in the conversation about state cannabis standards and regulations by viewing the CAC meeting and offering input during public comment periods. The public can also submit comments before the meeting by emailing [CAC@cannabis.ca.gov](mailto:CAC@cannabis.ca.gov).

Public comment periods will be held where noted on the agenda and after each agenda item. Remarks must address the specific agenda item for which a public comment period is being held. The amount of time allocated for each comment may be limited.

## Meeting Accessibility

DCC is committed to ensuring that our services, programs and meetings are accessible to all, including people with disabilities. The meeting will include closed captioning.

If you wish to request a disability-related accommodation, in accordance with federal and state law, email [CAC@cannabis.ca.gov](mailto:CAC@cannabis.ca.gov). Please provide your request at least five days before the meeting to help ensure availability of the requested accommodation.

## Additional Information

If you have any questions about this meeting notice, email [CAC@cannabis.ca.gov](mailto:CAC@cannabis.ca.gov).

## Meeting Agenda – Wednesday, July 10, 2024 at 9:00 a.m.

### Committee Administration

1. Call to order and roll call

### Public Comment for Items Not on the Agenda

2. Public comment for items not on the agenda

### Items for Discussion and Possible Recommendation

3. Cannabis Pet Products

*DCC is requesting feedback from the subcommittee on implementation of [Assembly Bill \(AB\) 1885 \(Kalra, Chapter 389, Statutes of 2022\)](#) which expands the Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA) to include regulation of the production and sale of cannabis products for animals. DCC is required to develop regulations for these products by July 1, 2025.*

*The subcommittee will discuss and may make recommendations to DCC on the following questions:*

- *What types of cannabis pet products should be allowed?*
- *Are there any types of cannabis pet products that should be prohibited?*
- *Should there be specific requirements or limits for different cannabinoids (THC, THCA, CBD, CBDA, CBC, CBG, THCV, etc.) in pet products?*
  - *For adult (human) use, cannabis edibles cannot exceed 10 mg THC per serving and 100 mg THC per package – should a different requirement be considered for animal products (e.g. mg/body weight)?*
- *In addition to [FDA requirements](#), the ingredient requirements for all pet food sold in California pursuant to the [Pure Pet Food Act](#) and its [implementing regulations](#), and the list of allowable pet food ingredients maintained by the [Association of American Feed Control Officials](#) (AAFCO), are there any other considerations for cannabis pet products?*
- *In addition to the existing rules in California for pet food labeling, what labeling requirements should be considered for cannabis animal products?*
  - *Should labels include a recommendation that a person consult a veterinarian prior to administering cannabis to an animal?*
  - *Should labels include a warning about contraindications or animal drug-interactions?*
  - *Should labels include a warning about signs of animal overdose/intoxication?*
- *What should DCC consider with respect to packaging requirements?*
- *Should there be any different laboratory testing requirements for animal products compared to human products?*



## Other Business

4. Future Agenda Items (Discussion only)
5. Adjournment